Sinocare announced recently that it successfully defended itself in court against trademark infringement claims brought by ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...

A new study led by researchers from Boston University Chobanian & Avedisian School of Medicine has found there is no consensus in how clinical experts interpret CGM reports from people without ...

Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM) to be approved by the FDA, Abbott has got the green light for its Lingo device - and ...

In June 2024, Abbott received a pair of clearances for its Libre Rio and Lingo CGM systems, both the company’s first to become available without a prescription. Based on its FreeStyle Libre ...

Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose levels in real-time in non-diabetics.

and tapping into the consumer market with the Lingo CGM. Additionally, Abbott expects to achieve 150 basis points of operating margin improvement, reflecting the success of its internal cost ...

Libre Drives Diabetes Care: Abbott’s Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Abbott's revenue for the fourth quarter of 2024 ... in recent years as it is the first continuous glucose monitoring [CGM] system that is available without the need to see a doctor for a prescription.